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Abstract 
Objectives: To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients 
with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram‑positive cocci (GPC), as well as 
its safety and pharmacoeconomic impact.
Methods: A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/
or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, 
at 3 months and at 1 year.
Results: Eighty‑three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 
49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microor‑
ganism was Staphylococcus aureus in BSI (49%) and coagulase‑negative staphylococci in IE (44.1%). All patients with 
IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow‑up, 8.8% mortality unrelated to IE, and 
2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI 
was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow‑up. No patient 
discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days 
for IE (283,187.45€).
Conclusions: DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It 
proved to be a cost‑effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic 
profile of this drug.
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Background
The incidence of infective endocarditis (IE) has risen over 
recent decades, attributable to improved patient sur-
vival and diagnostic techniques and the increased utili-
zation of invasive devices (e.g., urinary catheters, etc.) 
and procedures (e.g., haemodialysis, etc.) [1]. IE is most 
frequently caused by gram positive cocci (GPC), with 
Staphylococcus aureus being the most commonly isolated 
bacterium. Despite medical and surgical improvements, 
IE-associated mortality remains high, at around 30% in 
the first year [2]. Medical treatment of IE requires pro-
longed periods of parenteral antibiotic therapy that can 
involve long hospital stays, leading to the development 
of home antibiotic treatment programmes, now recom-
mended in clinical practice guidelines [3]. Some hospitals 
with insufficient resources to adopt this approach have 
implemented outpatient oral antibiotic treatment pro-
grammes, with promising results [4].
GPC bloodstream infection is usually associated with 
the use of a venous catheter and is one of the most fre-
quent nosocomial infections, reported to increase the 
morbidity and mortality of hospitalised patients by up 
to 12–25%, augmenting hospital costs [5]. The recom-
mended approach is at least 14 days of antibiotic therapy 
[6].
Dalbavancin (DBV), an antibiotic from the lipoglyco-
peptide family, is active against GPCs. Thanks to its phar-
macokinetic/pharmacodynamic (PK/PD) characteristics, 
a single dose of 1000  mg or 1500  mg IV achieves ade-
quate plasma and tissue concentrations to provide antibi-
otic coverage for 1 or 2 weeks, respectively [7]. However, 
few clinical data are available on its effectiveness against 
GPC IE or BSI [8–10].
The objective of this study was to evaluate the effective-
ness of DBV in clinical practice as consolidation therapy 
in patients with GPC IE or BSI and to determine the 
incidence of adverse effects and its pharmacoeconomic 
impact and cost-effectiveness.
Patients and methods
Study design
We conducted a multicentre, observational, retrospective 
study (in 14 Spanish hospitals) of hospitalised patients 
with GPC IE and/or BSI who received at least one dose of 
DBV prescribed by their attending physician in the clini-
cal setting. The study period ranged from 2016 (when 
DBV was approved by all participating hospitals) to 31 
December 2017. Patients were followed up for 12 months 
after their first dose of DBV. The study did not involve any 
direct pharmacological intervention and was approved by 
the ethics committee of the coordinating hospital, which 
was also responsible for the quality control of data from 
the participating hospitals.
Population
Inclusion criteria were: the presence of IE and/or BSI 
with microbiological isolation of GPCs, and the receipt 
of least one dose of DBV after providing written or ver-
bal informed consent to this treatment. Exclusion crite-
ria were: age under 18  years, pregnancy, EI and/or BSI 
caused by microorganisms other than GPC, moderate/
severe liver failure, and/or history of hypersensitivity to 
glycopeptides.
Variables
Data were gathered from the clinical history of the 
patients on the following variables: age and sex of the 
patient; length of hospital stray (days from date of admis-
sion to date of discharge); department at admission and 
discharge; patient comorbidities (age-adjusted Charlson 
index); the type of IE for which DBV was prescribed [def-
inite/probable, native/prosthetic, early/late); the device 
involved (pacemaker, implantable cardioverter-defibrilla-
tor); the presence of BSI (complicated, uncomplicated)]; 
previous and/or concomitant antibiotic therapy for the 
infection; the microorganism responsible; susceptibil-
ity testing results; the date of DBV administration and 
the dose; the need for surgery in patients with IE and 
the date; related and unrelated death in hospital or at 
12 months; recurrence; reinfection; adverse effects (AEs), 
including headache, nausea, diarrhoea, vomiting, rash; 
increased gamma-glutamyl transferase, diarrhoea from 
Clostridium difficile; and DBV discontinuation due to 
adverse event.
Definition of variables
Infectious endocarditis (IE) was defined according to 
2015 modified Duke criteria [3]. IE was considered early 
when within 12 months post-surgery and late when more 
than 12 months post-surgery [11].
• Nosocomial or healthcare-related IE was considered 
when symptom onset was observed after 48 h of hos-
pital admission or when an invasive procedure had 
been performed in hospital, nursing home or assisted 
care facility in the three months before the diagnosis, 
e.g., intravenous treatment, wound care, or haemodi-
alysis, etc. [12].
• BSI recurrence was defined by the reappearance of 
the same bacterial strain in blood cultures after com-
pletion of treatment [13].
• IE relapse was defined by a second episode of IE due 
to the same microorganism within three months of 
the first.
• IE reinfection was defined by another IE during the 
12-month follow-up caused by a different microor-
ganism from that identified in the original infection.
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• Mortality was evaluated as hospital mortality 
(death from any cause during hospital stay or the 
first 30 days post-discharge), and mortality at 3 and 
12  months related to IE (e.g., heart failure due to 
valve dysfunction) and not related to IE (e.g., can-
cer).
• Microbiological failure was defined by persistent or 
breakthrough BSI during the treatment of BSI or IE 
[13], or when the same microorganism was isolated 
in the blood culture of a patient with IE requiring 
surgery after completing antibiotic therapy.
• Complicated BSI was defined by the presence of sep-
tic metastases and/or the non-removal of a colonised 
catheter and/or no response at 48–72 h [13].
• The age-adjusted Charlson Comorbidity Index was 
used to assess the 10-year life expectancy of the 
patients [14].
Statistical analysis
The percentage effectiveness was calculated by perform-
ing two analyses, one taking account of all patients who 
received at least one dose of DBV and completed the fol-
low-up and the other also including the patients lost to 
the follow-up. In a descriptive analysis, absolute and rela-
tive frequencies (%) were calculated for qualitative vari-
ables, and means and standard deviations for quantitative 
variables with normal distribution or medians and 25th 
and 75th percentiles for quantitative variables with non-
normal distribution, as established by the Kolmogorov–
Smirnov test. p < 0.05 was considered significant. SPSS © 
20.0 was used for data analyses.
Cost analysis
In our evaluation of the economic impact of DBV, its cost 
was compared with the cost of antibiotics commonly 
used against GPC IE and BSI, including vancomycin, 
daptomycin, linezolid, and the cost was then multiplied 
by the mean number of days of DBV-covered treat-
ment in our patient cohort. We also analysed the sav-
ings in hospital costs obtained by using antibiotics for 
outpatient administration at a day hospital (intravenous 
daptomycin) or at home (oral linezolid). Doses of anti-
biotics used for cost analysis were: 1 g vancomycin/12 h 
(€13.80/day), 700  mg daptomycin/24  h (€140.14/day), 
600  mg linezolid/12  h (€71.40/day) and 1500  mg DVB 
to cover 14 days of treatment (€161.79/day). The cost of 
1 day of hospital stay was estimated as €495.95 (accord-
ing to prices published by the Regional Government of 
Andalusia).
Results
Population description
The study included 83 patients, 73.5% male, with a 
median age of 73  years (IQR: 53–77  years) and mean 
Charlson index of 2 (IQR: 1–4). BSI was present in 
59.1% of the patients, complicated in 41% and uncom-
plicated in 18.1%. Definite IE was present in 37.3% of 
the patients and probable IE in 3.6%.
Patients with IE
The median age of the 34 patients with IE was 73 years, 
and 73.5% were male; IE was definite in 91.1% and 
probable in 8.8%; 44.1% had prosthetic valve IE (29.4% 
late vs. 14.7% early), 32.4% native valve IE, and 23.5% 
pacemaker lead IE. IE affected the aortic valve in 50% of 
these patients, the mitral valve in 23.5%, and the tricus-
pid valve in 2.5%.
Among the microorganisms, isolated in these patients, 
44.1% were coagulase-negative staphylococci (CNS), 
29.4% Staphylococcus aureus (SA) (20.6% methicillin-
susceptible SA (MSSA) and 8.8% methicillin-resistant 
SA (MRSA), 11.8% streptococci and 8.8% Enterococcus 
faecalis. The reason for DBV administration was the 
achievement of early discharge in 91.2% of cases and 
the failure of previous antibiotic therapy in 8.8%. DBV 
administration reduced the hospital stay by 14  days 
(IQR: 7–17), producing a total decrease of 557 days. Out 
of the 17 (50%) patients with IE cases who received sur-
gery, 91.7% received DBV on the next day. The median 
number of days on antibiotics (68.6% daptomycin, 29.4% 
ceftriaxone, 23.5% vancomycin and 8.8% linezolid) 
before DBV administration did not significantly dif-
fer between operated and non-operated patients (14.7 
vs. 16.8  days, p = 0.529). The median interval between 
admission and surgery was 8 days (IQR: 6–15). Table 1 
exhibits the data for all study variables.
Patients with BSI
Forty-nine patients had GPC BSI, which was com-
plicated in 30.6% of cases; the mean patient age was 
67  years and the mean Charlson index was 2 (IQR: 
1–4) (see Additional file 1: Table S1). DBV was admin-
istered as first option in three patients and after the 
administration of another antibiotic, for a median of 
8 days (IQR: 0–15), in the remainder (93.8%). The rea-
son for DBV prescription was to facilitate hospital dis-
charge in 93.8% of cases. DBV administration achieved 
a reduction in hospital stay of 14  days (IQR: 7–14). 
The remaining characteristics of these patients are dis-
played in Table 2.
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Table 1 Characteristics of patients with infective endocarditis
N = 34
Age, median (IQR) 73 (63–81)
Male, n (%) 25 (73.5)
Charlson index, n (%) 2 (1–4)
Type of infection, n (%)
 Definite IE 31 (91.2)
 Probable IE 3 (8.8)
Endocarditis, n (%)
 Native 11 (32.4)
 Early prosthetic 5 (14.7)
 Late prosthetic 10 (29.4)
 Pacemaker lead 8 (23.5)
Valve affected, n (%)
 Aortic 17 (50)
 Mitral 8 (23.5)
 Tricuspid 1 (2.9)
Causative organism, n (%)
 MSSA 7 (20)
 MRSA 3 (8.6)
 CNS 15 (42.9)
 E. faecalis 3 (8.6)
Streptococcus spp. 7 (20)
 Patient received prior antibiotic therapy, n (%) 34 (100)
 Days of previous antibiotic treatment, median (IQR) 28 (17–35)
Prior antibiotic therapy, n (%)
 Daptomycin 24 (68.6)
 Ceftriaxone 10 (28.6)
 Linezolid 3 (8.6)
 Vancomycin 8 (22.9)
 Surgery, n (%) 12 (34.3)
 Surgery before administering DBV 11 (91.6)
Reason for DBV administration, n (%)
 Facilitate discharge 30 (88.6)
 Prior treatment failure 3 (8.6)
DBV dose, n (%)
 1000 mg (1 day), 500 mg (8 days) 10 (29.4)
 1000 mg 1 day 5 (14.7)
 1500 mg (1 day) 12 (35.3)
 1000 mg (1 day), 500 mg (8 days), 500 mg (15 days) 1 (2.9)
 1500 mg (1 day), 1000 mg (15 days) 3 (.8)
 1500 mg (1 day), 1000 mg (15 days, 30 days, 45 days) 1 (2.9)
 1000 mg (1 days), 500 mg every week/9 weeks 1 (2.9)
 1500 mg (1 days), 1000 mg every 2 weeks/10 weeks 1 (2.9)
 DBV‑covered days, median (IQR) 14 (14–21)
 Clinical cure, n (%) 34 (100)
 Microbiological cure, n (%) 33 (97.1)
 Follow‑up blood cultures: 17 (48.6)
 Negative follow‑up blood cultures 17 (100)
IE‑related death, n (%)
 During hospitalisation 0
 At 12 months 0
 Relapse, n (%) 0
Table 2 Bloodstream infection characteristics
N = 49
Age, median (IQR) 67 (50–75)
Male, n (%) 36 (73.5)
Charlson index, n (%) 2 (1–4)
Type of infection, n (%)
 Complicated bloodstream infection 34 (69.4)
 Uncomplicated bloodstream infection 15 (30.6)
Causative organism, n (%)
 MSSA 15 (30.6)
 MRSA 9 (18.4)
 CNS 17 (34.7)
 E. faecalis 1 (2)
 E. faecium 2 (4.1)
 Streptococcus 2 (4.1)
 Other 1 (2)
 No isolation 2 (4.1)
 Days of prior AB therapy, median (IQR) 8 (0–15)
 Prior antibiotic therapy, n (%) 46 (93.9)
 Daptomycin 22 (44.9)
 Ceftriaxone 10 (20.4)
 Linezolid 9 (18.4)
 Vancomycin 11 (22.4)
Reason for DBV administration, n (%)
 Facilitate discharge 38 (77.6)
 Prior treatment failure 1 (2)
 Toxicity 2 (4)
DBV dose, n (%)
 1000 mg (1 day), 500 mg (8 days) 14 (28.6)
 1000 mg 1 day 11 (22.4)
 1500 mg 1 day 21 (42.9)
 Other 3 (6.1)
 DBV‑covered treatment days (IQR) 14 (14)
 Clinical cure, n (%) 49 (100)
Microbiological cure
 Follow‑up blood cultures, n (%) 36 (73.5)
 Negative follow‑up blood cultures 35 (97.2)
 Death related to bloodstream infection, n (%) 0
 Relapse, n (%) 0
 Readmission for different reason 1 (2)
 Reduction in days of hospital stay (IQR) 14 (7–14)
 Total reduction, days 636
Table 1 (continued)
MSSA methicillin‑sensitive S. aureus; MRSA methicillin‑resistant S. aureus, CNS 
coagulase‑negative staphylococcus
N = 34
 Median reduction in hospital stay (IQR) 14 (7–17)
 Total reduction, days 557
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Effectiveness
IE
Of the 34 patients with IE, 15 (44.1%) had prosthetic 
valve IE, which was treated with surgery in 10 (66.7%) 
of these cases and resolved with antibiotic therapy alone 
in the remaining 5 (33.5%). Out of the 8 (23.5%) with 
pacemaker lead IE, 7 (87.5%) were cured with antibi-
otic therapy and removal of the system; the remaining 
patient (12.5%) was considered a failure, being initially 
diagnosed with pacemaker pocket infection due to S. 
epidermidis and treated by removal of the generator 
together with antibiotic therapy (daptomycin 10  mg/
kg/24  h/IV + gentamycin 5  mg/kg/24  h/IV + rifampicin 
600 mg/24 h/IV for 2 weeks, and a single dose of dalba-
vancin 1500  mg/IV); at one month, a haematoma was 
detected in the pocket of the extracted pacemaker, the 
leads were removed, and S. epidermidis was again iso-
lated. Out of the 11 (32.5%) patients with native valve 
endocarditis, 5 (45.4%) required surgery and the remain-
ing 6 were cured with antibiotic therapy alone (Table 3).
All patients with IE were clinically cured during their 
hospital stay and there was only one microbiological 
failure (in the patient with pacemaker lead IE).
The 12-month follow-up was completed by 33 (97.1%) 
of the patients with EI, with only one loss (due to the 
patient leaving the country). Three (9.1%) died for 
causes unrelated to DBV treatment: one for adenocar-
cinoma of the oesophagus, one for decompensated liver 
cirrhosis, and the third for a new episode of native IE 
at four, six and three months after hospital discharge, 
respectively. Two (6.1%) patients had a new episode 
of endocarditis: one had pacemaker lead endocardi-
tis caused by Serratia spp at 10  months after the first 
episode of PLE by S. epidermidis, which was treated by 
complete removal of the pacemaker system and antibi-
otics; and the other patient had native endocarditis due 
to MSSA at three months after the first NVE episode by 
a different microorganism, who was treated with DBV 
and met the clinical, microbiological and echocardio-
graphic criteria for a cure.
At 12  months, the proportion of patients cured of IE 
was 85.3% when the patient lost to the follow-up was 
included and 96.7% when only patients completing 
the one-year follow-up were considered. There was no 
relapse at 12 months.
BSI
A clinical cure was obtained in all of the 49 patients with 
GPC BSI, and post-treatment blood cultures ordered for 
36 (73.5%) of the patients were all negative. There were 
no relapses at 90  days. One patient was readmitted for 
BSI S. epidermidis and developed fever 1  month later, 
when he was diagnosed with pacemaker lead endocardi-
tis due to Corynebacterium.
Adverse events
Among the 83 patients who received DBV, 4.8% experi-
enced adverse effects: asthenia, self-limited rash, fever 
with self-limited shivering, and impaired renal function 
that was found by laboratory tests to have returned to its 
baseline status at one week. There was no grade 4 event 
or any event causing treatment discontinuation, and no 
patient developed colitis due to Clostridium difficile.
Pharmacoeconomic study
The DBV dose administered was designed to achieve a 
mean antibiotic coverage of 2 weeks. The cost of 2 weeks 
of treatment with the antibiotics under study was 193.20€ 
for vancomycin, 1960.20€ for daptomycin, 999.60€ for 
linezolid and 2265.00€ for DBV.
The mean reduction of 14 days in the hospital stay of 
DBV-treated patients represented an estimated saving of 
6938.26€. The total cost of 14 days of antibiotic therapy, 
including the cost of hospital stay, was 7131.46€ for van-
comycin, 8898.46€ for daptomycin, 999.6€ for linezolid 
and 2265€ for dalbavancin.
The total reduction in hospital stay in the present 
cohort was 636 days for patients with BSI (315,424.20€) 
and 557 days for those with IE (283,187.45€). Treatment 
with DBV allowed the early discharge of 71 patients 
(84.5%) with an overall saving of 1193  days (mean of 
14 days/patient, range 7–14).
Discussion
This cohort of 83 elderly patients with endovascular 
infection by GPC were predominantly male, and two 
in five had IE. Older patients are frequently polymedi-
cated, increasing the possibility of therapeutic failure 
due to poor treatment compliance [15] and the risk of 
drug interactions [16]. The pharmacokinetic/pharmaco-
dynamic properties of DBV mean that a single dose can 
provide antibiotic coverage for 1 or 2  weeks, favouring 
compliance to the treatment regimen, and this drug does 
not interact with cytochrome p450, reducing the likeli-
hood of potential drug interactions [17].
A clinical cure rate of 100% was achieved in both BSI 
and IE when DBV was used as a consolidation strategy in 
this study population, with a microbiological cure rate of 
100% in BSI and 97.1% in IE. Furthermore, no relapse or 
BSI- or IE-related death was recorded during the hospital 
stay or at 3 or 12 months post-discharge. In two-thirds of 
the patients with prosthetic IE, surgery was not required, 
and DBV was administered as consolidation therapy to 
facilitate discharge.
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The incidence of BSI has increased over recent decades, 
with no major improvements in its prognosis, and it is 
the seventh leading cause of death in Europe and North 
America [18]. IE is a severe disease mostly caused by 
GPC, with S. aureus being the most frequently implicated 
microorganism. It commonly affects older individuals 
and is associated with a high mortality rate despite a cor-
rect treatment [19]. DBV is a lipoglycopeptide approved 
for the treatment of skin and soft tissue infections. It was 
found to be more effective than vancomycin or linezolid 
to treat GPC BSI (100% vs. 85.7%) [18], and the only clini-
cal trial on its utilisation.
against GPC BSI also found a higher cure rate with 
DBV (87%) than with vancomycin (50%) [8]. In addition, 
a Spanish retrospective study on the administration of 
DBV in routine clinical practice observed a cure rate of 
84.1% in patients with BSI secondary to catheter infec-
tion [9]. There has been only one single-centre retrospec-
tive study on the effectiveness of DBV in GPC IE, which 
followed 27 patients for 2 years and reported a cure rate 
of 92.6% [10]. Out of the 7 (25.9%) patients with pros-
thetic valve IE, this was resolved by the antibiotic therapy 
alone in six and was treated by surgery in the remaining 
patient, whose IE was produced by Enterococcus faeca-
lis and who died 2  weeks post-surgery; out of the with 
device-related IE, a cure was achieved by surgery in all 
cases except for one patient whose device could not be 
completely removed [10].
To date, the treatment of choice for patients with pros-
thetic valve or medical device IE has been the combi-
nation of antibiotic therapy with valve replacement or 
removal of the complete system whenever possible [3]. 
In vitro studies on biofilm-associated infections reported 
that DBV is efficacious against prosthetic joint infections 
produced by staphylococci [20] or vancomycin-suscep-
tible Enterococci [21] and against catheter infections 
caused by MRSA and S. epidermidis [22]. These findings 
may explain the excellent outcomes achieved by DBV in 
our study, in which around half of the patients with pros-
thetic IE were cured with no need to remove the pros-
thetic material.
In the present study of DBV, the drug-related adverse 
event rate was below 5%, and there were no grade 4 
events or events prompting treatment discontinua-
tion; in addition, no Clostridium difficile strains were 
detected. In one clinical trial, a rate of 12.3% was 
obtained, with a severe adverse event rate of only 
0.3% [23], and another trial observed an adverse event 
rate below 5%, including nausea, diarrhoea, elevated 
LDH, headache, rash, and vomiting [24]. The dura-
tion of antibiotic treatment against IE ranges between 
4 and 8 weeks, usually leading to changes in intestinal 
microbiota and increasing the risk of adverse events, 
including C. difficile colitis. However, in comparison 
to other antibiotics habitually used to treat IE, these 
changes and the possibility of C. difficile infection are 
minimized when DBV is administered, in part explain-
ing the low adverse event rate observed with this drug 
[25].
DBV proved to be a cost-effective antibiotic in our 
study population. It was generally used as an antibiotic 
consolidation strategy, facilitating discharge, reducing 
stay, and maximising treatment adherence. The mean 
hospital stay is considered to be 7–14  days for BSI [18] 
and 4–8  weeks for IE, depending on the microorgan-
ism involved, the valve affected, the need for surgery, 
and associated complications [26]. Our results indicate 
that the selection of DBV can reduce the hospital stay of 
patients with complicated or uncomplicated BSI caused 
by DBV-susceptible GPCs and of patients with IE who 
do not require surgery or who are stable and complica-
tion-free post-surgery and only require hospitalization 
for the intravenous antibiotic administration. DBV has 
previously been described as a cost-effective antibiotic 
against GPC infections, including BSI and osteoarticular 
infections [27], and against skin and soft tissue infections 
caused by MRSA [28].
The limitations of our study include its retrospective, 
observational, non-interventional design and the lack of 
a comparator antibiotic. The strength of our study lies 
in the collaboration of 14 hospitals with considerable 
experience in endovascular infection, yielding the larg-
est sample to date of patients with GPC IE and/or BSI for 
analysis of the effectiveness of DBV in real-life clinical 
practice.
DBV appears to be effective against GPC IE and BSI 
as consolidation antibiotic therapy in patients who are 
already clinically stabilized. Besides the important clini-
cal advantages of DBV, including increased treatment 
adherence, its PK/PD profile offers major pharmacoeco-
nomic benefits, allowing the hospital stay to be signifi-
cantly reduced.
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